---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277571"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:21:45.454720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Erasca Q3 net loss $30.6M, cash $362M; patent issued for pan-RAS drug ERAS-0015

## Summary
- Net loss $30.6M ($0.11/sh) vs $31.2M in Q3 2024; R&D down to $22.5M from $27.6M.
- Cash $362.4M as of Sep 30, 2025 (down from $440.5M Dec 31); runway into H2 2028.
- U.S. composition of matter patent issued for ERAS-0015 covering composition through Sep 2043.
- Promoted Robert Shoemaker, Ph.D., from SVP research to chief scientific officer.
- Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.

## SEC filing metadata
- accession: 0001193125-25-277571
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/0001193125-25-277571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/eras-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277571
- JSON: https://secwatch.observer/filing/0001193125-25-277571.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.